Advertisement

Annals of Surgical Oncology

, Volume 21, Issue 11, pp 3646–3653 | Cite as

Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy

  • Hyung Soon Lee
  • Gi Hong Choi
  • Jin Sub ChoiEmail author
  • Kyung Sik Kim
  • Kwang-Hyub Han
  • Jinsil Seong
  • Sang Hoon Ahn
  • Do Young Kim
  • Jun Yong Park
  • Seung Up Kim
  • Beom Kyung Kim
Hepatobiliary Tumors

Abstract

Background

This study evaluated the down-staging efficacy and impact on resectability of concurrent chemoradiotherapy (CCRT) followed by hepatic arterial infusion chemotherapy (HAIC) in locally advanced hepatocellular carcinoma, and identified prognostic factors of disease-free survival (DFS) and overall survival (OS) after curative resection.

Methods

DFS and OS were investigated using clinicopathologic variables. Functional residual liver volume (FRLV) was assessed before CCRT and again before surgery in patients with major hepatectomy. Tumor marker response was defined as elevated tumor marker levels at diagnosis but levels below cutoff values before surgery (α-fetoprotein < 20 ng/mL, protein induced by vitamin K absence or antagonist-II < 40 mAU/mL).

Results

Of 243 patients who received CCRT followed by HAIC between 2005 and 2011, 41 (16.9 %) underwent curative resection. Tumor down-staging was demonstrated in 32 (78 %) of the resected patients. FRLV significantly increased from 47.5 to 69.9 % before surgery in patients who underwent major hepatectomy. In addition, the OS of the curative resection group was significantly higher than the OS of the CCRT followed by HAIC alone group (49.6 vs. 9.8 % at 5-year survival; p < 0.001). By multivariate analysis, the poor prognostic factors for DFS after curative resection were tumor marker non-response and the presence of a satellite nodule; however, tumor marker non-response was the only independent poor prognostic factor of OS.

Conclusions

CCRT followed by HAIC increased resectability by down-staging tumors and increasing FRLV. Curative resection may provide good long-term survival in tumor marker responders who undergo CCRT followed by HAIC.

Keywords

Overall Survival Curative Resection Portal Vein Embolization Biliary Complication Portal Vein Tumor Thrombus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

The authors are grateful to Dong-Su Jang (Medical Illustrator, Medical Research Support Section, Yonsei University College of Medicine, Seoul, South Korea) for his help with the figures.

Conflict of interest

All authors have no conflict of interest, financial or otherwise.

Supplementary material

10434_2014_3652_MOESM1_ESM.docx (242 kb)
Supplementary material 1 (DOCX 242 kb)

References

  1. 1.
    Fan ST, Mau Lo C, Poon RT, et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg. 2011;253:745–58.PubMedCrossRefGoogle Scholar
  2. 2.
    Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985;56:918–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Irtan S, Chopin-Laly X, Ronot M, Faivre S, Paradis V, Belghiti J. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int. 2011;31:740–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Sitzmann JV, Abrams R. Improved survival for hepatocellular cancer with combination surgery and multimodality treatment. Ann Surg. 1993;217:149–54.PubMedCrossRefPubMedCentralGoogle Scholar
  5. 5.
    Meric F, Patt YZ, Curley SA, Chase J, Roh MS, Vauthey JN, et al. Surgery after downstaging of unresectable hepatic tumors with intra-arterial chemotherapy. Ann Surg Oncol. 2000;7:490–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Ben-Josef E, Normolle D, Ensminger WD, et al. Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–47.PubMedCrossRefGoogle Scholar
  7. 7.
    Koom WS, Seong J, Han KH, Lee do Y, Lee JT. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys. 2010;77:1433–40.PubMedCrossRefGoogle Scholar
  8. 8.
    Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995–1003.PubMedCrossRefGoogle Scholar
  9. 9.
    Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Lau WY, Lai EC. Salvage surgery following downstaging of unresectable hepatocellular carcinoma: a strategy to increase resectability. Ann Surg Oncol. 2007;14:3301–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Seong J, Park HC, Han KH, Chon CY, Chu SS, Kim GE, et al. Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res. 2003;27:30–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Kim BK, Ahn SH, Seong JS, et al. Early alpha-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int. 2011;31:369–76.PubMedCrossRefGoogle Scholar
  13. 13.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Chon YE, Choi GH, Lee MH, et al. Combined measurement of preoperative alpha-fetoprotein and des-gamma-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer. 2012;131:2332–41.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamamoto K, Imamura H, Matsuyama Y, et al. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795–804.PubMedCrossRefGoogle Scholar
  16. 16.
    Mullen JT, Ribero D, Reddy SK, et al. Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg. 2007;204:854–62; discussion 62–4.Google Scholar
  17. 17.
    Edge SB CM, Compton CC. AJCC cancer staging manual. 7th ed. Chicago: Springer; 2009.Google Scholar
  18. 18.
    Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.PubMedCrossRefGoogle Scholar
  19. 19.
    Farges O, Belghiti J, Kianmanesh R, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg. 2003;237:208–17.PubMedPubMedCentralGoogle Scholar
  20. 20.
    Azoulay D, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Ann Surg. 2000;232:665–72.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Clavien PA, Selzner N, Morse M, Selzner M, Paulson E. Downstaging of hepatocellular carcinoma and liver metastases from colorectal cancer by selective intra-arterial chemotherapy. Surgery. 2002;131:433–42.PubMedCrossRefGoogle Scholar
  22. 22.
    Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung TW. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg. 2004;240:299–305.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Choi GH, Han DH, Kim DH, et al. Outcome after curative resection for a huge (≥10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg. 2009;198:693–701.PubMedCrossRefGoogle Scholar
  24. 24.
    Siriwardana RC, Lo CM, Chan SC, Fan ST. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case–control study. World J Surg. 2012;36:1640–6.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Wakabayashi H, Ishimura K, Okano K, et al. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer. 2001;92:2384–90.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu CL, Fan ST, Cheung ST, Lo CM, Ng IO, Wong J. Anterior approach versus conventional approach right hepatic resection for large hepatocellular carcinoma: a prospective randomized controlled study. Ann Surg. 2006;244:194–203.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Koo J, Fung K, Siu KF, et al. Recovery of malignant tumor cells from the right atrium during hepatic resection for hepatocellular carcinoma. Cancer. 1983;52:1952–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96.PubMedCrossRefGoogle Scholar
  29. 29.
    Imada H, Kato H, Yasuda S, et al. Compensatory enlargement of the liver after treatment of hepatocellular carcinoma with carbon ion radiotherapy: relation to prognosis and liver function. Radiother Oncol. 2010;96:236–42.PubMedCrossRefGoogle Scholar
  30. 30.
    Chen MF, Hwang TL, Hung CF. Human liver regeneration after major hepatectomy: a study of liver volume by computed tomography. Ann Surg. 1991;213:227–9.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008;247:49–57.PubMedCrossRefGoogle Scholar
  32. 32.
    Boonstra EA, de Boer MT, Sieders E, Peeters PM, de Jong KP, Slooff MJ, et al. Risk factors for central bile duct injury complicating partial liver resection. Br J Surg. 2012;99:256–62.PubMedCrossRefGoogle Scholar
  33. 33.
    Yoshioka R, Saiura A, Koga R, Seki M, Kishi Y, Yamamoto J. Predictive factors for bile leakage after hepatectomy: analysis of 505 consecutive patients. World J Surg. 2011;35:1898–903.PubMedCrossRefGoogle Scholar
  34. 34.
    Zimmitti G, Roses RE, Andreou A, Shindoh J, Curley SA, Aloia TA, et al. Greater complexity of liver surgery is not associated with an increased incidence of liver-related complications except for bile leak: an experience with 2,628 consecutive resections. J Gastrointest Surg. 2013;17(1):57–64; discussion 64–5.Google Scholar
  35. 35.
    Sadamori H, Yagi T, Shinoura S, et al. Risk factors for major morbidity after liver resection for hepatocellular carcinoma. Br J Surg. 2013;100:122–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Guha C, Kavanagh BD. Hepatic radiation toxicity: avoidance and amelioration. Semin Radiat Oncol. 2011;21:256–63.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Lau WY, Leung TW, Lai BS, Liew CT, Ho SK, Yu SC, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma. Ann Surg. 2001;233:236–41.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis. 2001;5:145–59.PubMedCrossRefGoogle Scholar
  39. 39.
    Vora SR, Zheng H, Stadler ZK, Fuchs CS, Zhu AX. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist. 2009;14:717–25.PubMedCrossRefGoogle Scholar
  40. 40.
    Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446–52.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Hyung Soon Lee
    • 1
  • Gi Hong Choi
    • 1
  • Jin Sub Choi
    • 1
    Email author
  • Kyung Sik Kim
    • 1
  • Kwang-Hyub Han
    • 2
  • Jinsil Seong
    • 3
  • Sang Hoon Ahn
    • 2
  • Do Young Kim
    • 2
  • Jun Yong Park
    • 2
  • Seung Up Kim
    • 2
  • Beom Kyung Kim
    • 2
  1. 1.Department of SurgeryYonsei University College of MedicineSeoulRepublic of Korea
  2. 2.Department of Internal MedicineYonsei University College of MedicineSeoulRepublic of Korea
  3. 3.Department of Radiation OncologyYonsei University College of MedicineSeoulRepublic of Korea

Personalised recommendations